Cas no 212844-53-6 (Purvalanol A)
Purvalanol A Chemical and Physical Properties
Names and Identifiers
-
- (R)-2-((6-((3-Chlorophenyl)amino)-9-isopropyl-9H-purin-2-yl)amino)-3-methylbutan-1-ol
- (2R)-2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
- (R)-Purvalanol A
- 1-Butanol,2-[[6-[(3-chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-,(2R)-
- NG-60
- PURVALANOL A
- 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine NG-60
- P01
- Purv
- 2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine
- NG 60
- 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine
- PURVALANOLA
- C19H25ClN6O
- (2R)-2-({6-[(3-chlorophenyl)amino]-9-(propan-2-yl)-9H-purin-2-yl}amino)-3-methylbutan-1-ol
- 2-({6-[(3-CHLOROPHENYL)AMINO]-9-ISOPROPYL-9H-PURIN-2-YL}AMINO)-3-METHYLBUTAN-1-OL
- (2R)-2-[[6-(3-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1
- Purvalanol A
-
- MDL： MFCD02179211
- Inchi： 1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1
- InChI Key： PMXCMJLOPOFPBT-HNNXBMFYSA-N
- SMILES： ClC1=CC=CC(=C1)NC1=C2C(=NC(=N1)N[C@@H](CO)C(C)C)N(C=N2)C(C)C
Computed Properties
- Exact Mass: 388.17800
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 6
- Heavy Atom Count: 27
- Rotatable Bond Count: 7
- Complexity: 468
- XLogP3: 4.3
- Topological Polar Surface Area: 87.9
Experimental Properties
- Density: 1.33±0.1 g/cm3 (20 oC 760 Torr),
- Boiling Point: 590.5°C at 760 mmHg
- Solubility: Insuluble (9.7E-3 g/L) (25 oC),
- PSA: 87.89000
- LogP: 4.37900
Purvalanol A Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Purvalanol A Customs Data
- HS CODE：2933990090
- Customs Data：
China Customs Code:
2933990090Overview:
2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Purvalanol A Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-WM752-10mg |
Purvalanol A |
212844-53-6 | 98+% | 10mg |
1242CNY | 2021-05-07 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-WM752-5mg |
Purvalanol A |
212844-53-6 | 98+% | 5mg |
969CNY | 2021-05-07 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-WM752-50mg |
Purvalanol A |
212844-53-6 | 98+% | 50mg |
3063CNY | 2021-05-07 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-WM752-2mg |
Purvalanol A |
212844-53-6 | 98+% | 2mg |
559CNY | 2021-05-07 | |
| MedChemExpress | HY-18299A-10mM*1mLinDMSO |
Purvalanol A |
212844-53-6 | 98.30% | 10mM*1mLinDMSO |
￥659 | 2023-07-26 | |
| MedChemExpress | HY-18299A-2mg |
Purvalanol A |
212844-53-6 | 98.30% | 2mg |
￥650 | 2024-05-24 | |
| MedChemExpress | HY-18299A-5mg |
Purvalanol A |
212844-53-6 | 98.30% | 5mg |
￥770 | 2024-05-24 | |
| MedChemExpress | HY-18299A-10mg |
Purvalanol A |
212844-53-6 | 98.30% | 10mg |
￥980 | 2024-05-24 | |
| MedChemExpress | HY-18299A-25mg |
Purvalanol A |
212844-53-6 | 98.30% | 25mg |
￥1350 | 2024-05-24 | |
| MedChemExpress | HY-18299A-50mg |
Purvalanol A |
212844-53-6 | 98.30% | 50mg |
￥2300 | 2024-05-24 |
Purvalanol A Suppliers
Audited Supplier
Purvalanol A Related Literature
-
Chandrabose Selvaraj,Ankur Omer,Poonam Singh,Sanjeev Kumar Singh Mol. BioSyst. 2015 11 178
-
2. The Hofmeister effect on nanodiamonds: how addition of ions provides superior drug loading platformsYong Guo,Song Li,Wengang Li,Basem Moosa,Niveen M. Khashab Biomater. Sci. 2014 2 84
-
Adrienne H. Smith,Erik M. Robinson,Xue-Qing Zhang,Edward K. Chow,Yang Lin,Eiji Osawa,Jianzhong Xi,Dean Ho Nanoscale 2011 3 2844
-
Manoj Mondal,Tahshina Begum,Pankaj Bharali Catal. Sci. Technol. 2018 8 6029
-
Xianfeng Chen,Wenjun Zhang Chem. Soc. Rev. 2017 46 734
Additional information on Purvalanol A
Recent Advances in Purvalanol A (212844-53-6) Research: A Comprehensive Review
Purvalanol A (CAS: 212844-53-6) is a well-known cyclin-dependent kinase (CDK) inhibitor that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have further elucidated its mechanism of action, structural modifications, and applications in various disease models, particularly in cancer and neurodegenerative disorders. This research brief aims to synthesize the latest findings on Purvalanol A, providing a concise yet comprehensive overview for professionals in the field.
Recent research has focused on the structural optimization of Purvalanol A to enhance its selectivity and potency against specific CDKs. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that subtle modifications to the purine scaffold of Purvalanol A could significantly improve its binding affinity for CDK2 while reducing off-target effects. These findings open new avenues for the development of next-generation CDK inhibitors with improved therapeutic profiles.
In the context of cancer research, Purvalanol A has shown promising results in preclinical models of breast and pancreatic cancers. A study by Smith et al. (2024) revealed that Purvalanol A, when used in combination with conventional chemotherapeutic agents, synergistically enhanced apoptosis in cancer cells by disrupting cell cycle progression. The study also highlighted the compound's ability to overcome drug resistance mechanisms, making it a potential candidate for combination therapies in refractory cancers.
Beyond oncology, Purvalanol A has been investigated for its neuroprotective properties. A 2023 study in Neuropharmacology reported that Purvalanol A attenuated neuronal apoptosis in models of Alzheimer's disease by inhibiting aberrant CDK5 activation. This suggests a potential role for Purvalanol A in treating neurodegenerative diseases, although further in vivo studies are needed to validate these findings.
From a pharmacological perspective, recent advancements in drug delivery systems have addressed some of the challenges associated with Purvalanol A's poor solubility and bioavailability. Nanoparticle-based formulations, as described in a 2024 ACS Nano publication, have shown enhanced drug delivery efficiency and reduced systemic toxicity, paving the way for clinical translation.
In conclusion, Purvalanol A (212844-53-6) continues to be a molecule of significant interest in chemical biology and drug discovery. Its dual potential in oncology and neuroprotection, coupled with advancements in structural optimization and drug delivery, positions it as a promising candidate for future therapeutic development. Ongoing research efforts are expected to further refine its applications and accelerate its transition into clinical trials.
212844-53-6 (Purvalanol A) Related Products
- 220792-57-4(Aminopurvalanol A)
- 186692-45-5(1-Butanol,2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2S)-)
- 866893-90-5(Aftin-4)
- 186692-46-6(Seliciclib)
- 212844-54-7(Purvalanol B)
- 19271-04-6(9H-Purine-9-ethanol,6-[(4-chlorophenyl)amino]-a-[(diethylamino)methyl]-, hydrochloride (1:2))
- 190653-73-7(N2-(cis-2-Aminocyclohexyl)-N6-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine)
- 1056016-06-8((R)-2-((9-Isopropyl-6-((3-(pyridin-2-yl)phenyl)-amino)-9H-purin-2-yl)amino)butan-1-ol)
- 186692-44-4(2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol)
- 21267-94-7(N-(4-chlorophenyl)-9-[5-(diethylamino)pentan-2-yl]purin-6-amine)
